The Cancer SIGNAL: Recent Episodes
GRAIL
The Cancer SIGNAL brings together experts from the cancer community to discuss the latest innovations transforming cancer detection and shifting the cancer paradigm. The podcast is presented by GRAIL and hosted by Kim Thiboldeaux, former CEO and Executive Chair of the Cancer Support Community.
Host Rayshawnda Madison connects with Roger, a returning guest who first shared his story in 2023 after receiving a Cancer Signal Detected result from the Galleri multi-cancer early detection (MCED) test. Follow-up testing led to a stage II pancreatic cancer diagnosis.
Now, three years later, Roger reflects on how life has evolved since completing treatment, what survivorship looks like for him today, and the mindset that helped him move forward. He also shares how the experience changed his relationship with health, why he remains vigilant, and what motivates him to continue raising awareness about MCED testing.
The overall sensitivity in study participants with pancreas cancer was 83.7%. (61.9% for stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV).
The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.
Transcripts: https://grail.com/podcast/
Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/
See Important Safety Information: https://www.galleri.com/safety-information
In this episode, Robert, a carpenter from the Midlands in England and a participant in the NHS-Galleri trial, joins host Shawnda Madison to share his experience.
After enrolling in the trial, Robert received a Cancer Signal Detected result from the Galleri multi-cancer early detection (MCED) test despite having no symptoms. The initial diagnostic evaluation did not identify cancer, but a subsequent Galleri test the following year returned the same result, leading his care team to continue investigating.
Eventually, a biopsy revealed a small HPV-related cancer at the base of his tongue. Robert reflects on the uncertainty of waiting for answers, the treatment and recovery that followed, and how the experience changed the way he thinks about health, screening, and the value of finding cancer earlier.
Transcripts: https://grail.com/podcast/
Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.
See Important Safety Information: https://www.galleri.com/safety-information
The overall sensitivity in study participants with head and neck cancer was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV).
Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
Kevin McFarland, a lieutenant with his local fire department, and Dr. Robert Merritt, a thoracic surgeon who helped diagnose and treat Kevin, share how the Galleri multi-cancer early detection (MCED) test unexpectedly revealed that Kevin had a signal for esophageal cancer—despite having no symptoms. The test, offered by the fire department where Kevin works, led to further medical exams that identified his specific type of cancer. Kevin reflects on the emotional, mental, and physical impact of his diagnosis and treatment, the importance of early detection, and how the experience renewed his appreciation for his health and family and gave him "a new lease on life." Dr. Merritt credits the Galleri test and early detection for Kevin's positive prognosis and recovery. Their story highlights the critical role of accessibility, awareness, and advocacy in cancer detection.
Watch the full episode on YouTube: https://www.youtube.com/watch?v=BVOJXdWUkCo
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.
See Important Safety Information: http://bit.ly/33m8pFa
The overall sensitivity in study participants with esophageal cancer was 85.0% (12.5% for stage I, 64.7% stage II, 94.1% stage III, 100% stage IV).
Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
In this episode of The Cancer SIGNAL, Nima Nabavizadeh, MD, an associate professor of radiation medicine at Oregon Health & Science University (OHSU) and the chief medical officer at the Cancer Early Detection Advanced Research Center (CEDAR) at OHSU, joins host Susanna Quinn to share the results from the groundbreaking GRAIL PATHFINDER 2 clinical trial unveiled at the European Society for Medical Oncology (ESMO 2025) Congress. As the principal investigator for the trial, which examined the safety and performance of the Galleri multi-cancer early detection test, Dr. Nabavizadeh discusses why the findings are pivotal for patients and could potentially redefine early cancer detection.
Watch the full episode on YouTube: https://youtu.be/owhDC8vH1hw
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.
See Important Safety Information: http://bit.ly/33m8pFa
Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
In this episode of The Cancer SIGNAL, Tad Carper, Senior VP of Communications for the Dallas Cowboys, shares how a multi-cancer early detection (MCED) screening unexpectedly revealed a cancer signal for head and neck cancer—despite experiencing no symptoms. The test, sponsored for the team’s assistant coaches by quarterback Dak Prescott’s foundation, Faith Fight Finish, was the first step toward Tad’s stage two cancer diagnosis. Tad reflects on the emotional and mental impact of his diagnosis, the importance of early detection, and how the experience reshaped his values—deepening his appreciation for life, relationships, and the power of proactive health care. His story highlights the critical role of accessibility, awareness, and advocacy in cancer detection, and his commitment to “paying it forward” by helping others take early action in their own health journeys.
Watch the full episode on YouTube: https://www.youtube.com/watch?v=WuManHvHtS4
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider–recommended screening tests.
See Important Safety Information: http://bit.ly/33m8pFa
The overall sensitivity in study participants with head and neck cancer was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV).
Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
At a semiannual primary care visit, Jack’s doctor mentioned multi-cancer early detection (MCED) testing. Though Jack wasn’t experiencing symptoms, and has no family history of cancer, he decided to take the test. Two Cancer Signal Detected results from MCED screening tests taken six months apart helped his care team determine the necessary diagnostics that confirmed an early-stage cancer diagnosis. Listen to Jack’s story to learn more about the impact early cancer detection had on his life.
Watch the full episode on YouTube: https://youtu.be/p8fFVshFWJk
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.
See Important Safety Information: http://bit.ly/33m8pFa
Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
Dr. Patrick McGill was instrumental in introducing Community Health Network to multi-cancer early detection (MCED) testing and integrating it into routine screenings offered to patients. Dr. McGill is Executive Vice President and Chief Transformation Officer at Community Health Network, and as a practicing primary care physician he believes strongly in the importance of catching cancer as early as possible to improve outcomes for patients. In this episode he shares how MCED has made an impact at Community Health Network.
Watch the full episode on YouTube: https://youtu.be/X9PyQeiO0HM
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.
Rx only. See Important Safety Information: http://bit.ly/33m8pFa
Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
How does cancer screening fit into one’s longevity goals? Dr. Ummat, a preventative medicine physician dedicated to changing the approach to aging, shares insights on the role of preventative care in maintaining long-term health, why proactive screening matters, and how new technologies like multi-cancer early detection testing can change the way we screen for cancer. Watch the full episode on YouTube: https://youtu.be/D0Hi4NLC-qo
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests. See Important Safety Information: http://bit.ly/33m8pFa Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
Dr. Eric Klein, Distinguished Scientist at GRAIL, provides a research update from GRAIL’s 2024 findings on multi-cancer early detection (MCED) testing, presented at ASCO, ESMO, AACR and more. He explores insights from the first real-world evaluation of repeat multi-cancer early detection testing, data on how multi-cancer early detection (MCED) testing is helping cancer survivors by detecting recurrence and new cancers, and findings on using MCED to detect high grade, clinically significant prostate cancer over indolent cases. Plus, the economic and emotional impacts of cancer screening, and three insightful case studies.
Watch the full episode on YouTube: https://youtu.be/QU6s3P1B5Bo
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.
Rx only. See Important Safety Information: https://www.galleri.com/safety-information
Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
At their doctor’s recommendation, Rich and Staci each took a multi-cancer early detection test during a routine checkup. Despite having no symptoms, Rich received a Cancer Signal Detected result, while Staci, who had a strong family history of cancer, did not. Listen to their story and learn about the impact of early cancer detection.
Watch the full episode on YouTube: https://youtu.be/NKY3lX9PGYs
View Rich and Staci’s story: https://youtu.be/z7M_ebq4Tj4?si=-C9cGsmx7MFzcKzc
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.
See Important Safety Information: http://bit.ly/33m8pFa
Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
Seven in 10 Americans are behind on at least one routine cancer screening. Jody Hoyos, CEO of the Prevent Cancer Foundation, joins Susanna to discuss the critical role of early cancer detection. She addresses the most common misconceptions about cancer screening and explains the importance of proactive screening, even when no symptoms are present.
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
Introducing our new host, Susanna Quinn! Susanna is a cancer survivor, entrepreneur, writer and philanthropist. Diagnosed with stage three ovarian cancer in 2019, Susanna underwent aggressive treatment and achieved cancer-free status by September of the same year. In this episode, Kim Thiboldeaux, the Cancer SIGNAL’s inaugural host, interviews Susanna about her cancer story and passes the torch.
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
Dr. Scout, Executive Director of the National LGBT Cancer Network, discusses how the LGBTQ+ community faces unique challenges in cancer screening. Dr. Scout highlights the increased cancer risks due to social factors, like discrimination and medical mistrust, and emphasizes the importance of inclusive healthcare provider training. The National LGBT Cancer Network works to educate both the community and providers, runs support groups for LGBTQ+ cancer survivors, and is developing a more comprehensive list of welcoming providers.
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
Jon Rendina and Dwight Venson of Whitman-Walker, a healthcare center historically focused on the LGBTQ+ community, join us to delve into how LGBTQ+ people and people of color face disparities in cancer incidence. Whitman-Walker, Cancer Support Community, and GRAIL are collaborating on INCLUDE, a study to evaluate multi-cancer early detection (MCED) testing’s impact within federally qualified health centers. The goal: make this kind of cancer screening available to more people in the future. Jon and Dwight discuss barriers to access, how LGTBQ+ and minority experiences of cancer care can be different, and how MCED testing may play a role in helping underserved groups.
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
Diverse clinical trials provide more meaningful data to researchers, but too many trials are based around monolithic audience groups. In early disease detection, particularly in conditions like cancer, diversity in clinical trials is especially important. Our guests, Eucharia Borden of the cancer nonprofit Family Reach and Dr. Gary Puckrein of the National Minority Quality Forum, discuss why diversity in clinical trials is critical and how to foster inclusivity in clinical research, getting us closer to healthcare equity.
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
After supporting her husband through his shocking cancer experience, Cindy decided to take a multi-cancer early detection test as recommended by her doctor. She was once again shocked when she received a “cancer signal detected” result, leading to a cancer diagnosis. Join us to hear about Cindy’s experience with early detection, treatment, and eventual remission, and what she learned along the way.
We want your feedback! Please take our podcast survey: https://bit.ly/42R4wGi
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
Join host Kim Thiboldeaux and Krissa Smith, VP of Mission Partnerships at Susan G. Komen, as they continue unraveling how the BRCA gene and other DNA mutations impact hereditary cancer risk. In this episode, Krissa shares personal stories about her family's experiences with genetic testing and how they’ve chosen to respond. Krissa also discusses cancer screening best practices and how multi-cancer early detection testing can play a role.
Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
Krissa Smith, Vice President of Mission Partnerships at Susan G. Komen, joins us to discuss the complexities of the BRCA gene and its impact on hereditary cancer risk. Krissa shares her family's experiences with genetic mutations, including the p53 gene, and explains the importance of genetic testing and how it can work in partnership with evolving cancer screening technology. Stay tuned for part 2 to learn more about genetics, cancer risk, and the importance of early detection.
Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
Meet Tami, manager of a Christmas tree farm in rural Oregon. Cancer has had a profound impact on Tami’s life, from her grandmother's diagnosis more than 30 years ago to her own 2017 diagnosis to her participation in the PATHFINDER study. Tami shares what she’s learned about cancer and the importance of proactive screening, including her own experiences with multi-cancer early detection (MCED) testing.
Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
In the years since the COVID-19 pandemic began, cancer screening has changed, necessitating inventive strategies. Epidemiologists Dr. Alpa Patel (Senior Vice President of Population Science, American Cancer Society) and Dr. Tina Clarke (Vice President of Epidemiology and Distinguished Scientist, GRAIL) return to The Cancer SIGNAL to discuss how the pandemic changed access to cancer screening, the impact it had on diagnosing cancer, and where that leaves the screening landscape today.
Please take our survey to share your thoughts on The Cancer SIGNAL: https://bit.ly/3sQkbrN
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
What did researchers learn when they studied a multi-cancer early detection test in a population of more than 6,000 patients? The PATHFINDER study, recently published in The Lancet, explored that question and produced useful insights. Dr. Chuck McDonnell, a radiologist with Sutter Medical Group and principal investigator for PATHFINDER, joins this episode to discuss how the study worked, highlights of the results, and what they could mean for the future of cancer screening.
Transcripts available at https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
The American Indian Cancer Foundation is on a mission to eliminate the cancer burdens of Indigenous people through improved access to prevention, early detection, treatment and survivor support. Melissa Buffalo, CEO of the Foundation, discusses the cancer burden faced by Native Americans and what her Foundation is doing to reduce disparities in care.
Transcripts available at https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
When Roger received a confirmed diagnosis of pancreatic cancer, an aggressive, fast-growing and often deadly cancer, one doctor called him “lucky,” since Roger’s cancer was found at an early stage and before he showed any symptoms. Roger had been screened with a multi-cancer early detection test as part of his efforts to take care of his health. Learn more about Roger’s story and hear how he is doing today.
Transcripts available at https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/
Lynch syndrome is an inherited disorder associated with many different cancers including ovarian, uterine, pancreatic and, most commonly, colorectal. It is estimated that about one in 279 people are Lynch syndrome carriers, or about 1 million people in the U.S. Dr. Jordan Karlitz, Senior Medical Director at GRAIL, and Robin Dubin, Executive Director and Co-founder of AliveandKick’n – a patient advocacy organization focused on Lynch syndrome – join The Cancer SIGNAL to discuss risks associated with hereditary cancer predispositions, the need for tailored screening programs and how multi-cancer early detection could be used to look for cancers associated with Lynch syndrome.
AliveandKick’n: https://www.aliveandkickn.org/
Sign up for GRAIL’s monthly newsletter: http://bit.ly/3ZBt6IK
When it comes to cancer, there are many types of tests that can provide critical information–tests that can determine one’s risk of getting cancer, tests that screen for the presence of cancer, and tests that assess mutations or specific characteristics of a person’s cancer to inform treatment paths. Dr. Eric Klein, Distinguished Scientist at GRAIL, joins The Cancer SIGNAL to discuss the different types of cancer tests and each of their purposes.
Sign up for GRAIL’s monthly newsletter: http://bit.ly/3ZBt6IK
Despite significant progress in cancer care, critical health disparities in cancer incidence and outcomes still exist. Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum, joins The Cancer SIGNAL to share his thoughts on improving diversity in clinical trials, the impact of health disparities on cancer outcomes, and why we need to move quickly to expand early cancer detection among underserved and marginalized communities.
National Minority Quality Forum: https://www.nmqf.org/
Sign up for GRAIL’s monthly newsletter: http://bit.ly/3ZBt6IK
Cancer is expected to claim the lives of more than 609,000 Americans in 2023 alone, according to the American Cancer Society. Dr. Alpa Patel, Senior Vice President of Population Science at the American Cancer Society, and Dr. Tina Clarke, Epidemiology Vice President and Distinguished Scientist at GRAIL, explore the evolution of how we measure and approach cancer risk and what steps people can take to prevent and detect cancer early, when treatment is more likely to be successful.
Learn more about the American Cancer Society: https://www.cancer.org/
Read Dr. Patel’s and Dr. Clarke’s paper, “Rethinking risk assessment in the era of multi-cancer early detection”: https://aacrjournals.org/cancerpreventionresearch/article/16/1_Supplement/IA025/711907
Sign up for GRAIL’s monthly newsletter: http://bit.ly/3ZBt6IK
March is Colorectal Cancer Awareness Month, and we had the opportunity to feature two guests from the Colorectal Cancer Alliance, a nonprofit whose mission is to provide support to people affected by colorectal cancer, raise awareness of preventive measures and inspire efforts to fund critical research. Michael Sapienza, CEO of the Alliance, and Dr. Charles R. Rogers, an endowed associate professor of epidemiology and social sciences at the Medical College of Wisconsin and an advisor to the Alliance, discuss why they’re passionate about colorectal cancer awareness, the newest guidelines for screening, and efforts to make colorectal cancer care and outcomes more equitable. https://www.ccalliance.org/ https://bluehq.org/ Sign up for GRAIL’s monthly newsletter: http://bit.ly/3ZBt6IK
From the early 20th century discovery that cancer is a disease of the genome to having sequenced more than one million humans’ genomes today - this is just some of the history Amoolya Singh, Senior Vice President of Data Science and Chief Scientific Officer at GRAIL discusses when she shares the role of genomics and AI in cancer detection, what’s needed for population-scale screening tests, and what she’s excited about for the future.
Full transcript available at https://bit.ly/40T48FD
Sign up for GRAIL’s monthly newsletter: http://bit.ly/3lwlwjn
Valerie kept active, felt healthy, and enjoyed spending time with her friends and family. Although she didn’t have symptoms, she took the Galleri test, which found a positive cancer signal. After additional evaluations, it was confirmed she had early-stage gallbladder cancer and was able to take action. Valerie shares her experience taking the test, what the results meant, her treatment journey and outlook for the future.
Step into the lab with Rita Shaknovich, vice president of medical affairs and head of clinical laboratories at GRAIL, as she dives into the science behind the Galleri test and brings to life the process that a Galleri test sample goes through from beginning to end.
Many U.S. veterans may be at an increased risk of cancer, making access to early detection critical to their health. Dr. Charles Atwood, pulmonologist and lead researcher for the REFLECTION Study at the VA Pittsburgh Healthcare System, joins The Cancer SIGNAL to discuss the work being done to expand early cancer detection for veterans.
GRAIL’s founder, Dr. Rick Klausner and president, Joshua Ofman, join host Kim Thiboldeaux to discuss the science behind multi-cancer early detection, the technology being pioneered, and how the tests have the potential to help find cancer earlier in people with elevated risk.
Each month, Kim Thiboldeaux, former CEO and Executive Chair of the Cancer Support Community, will host a discussion around multi-cancer early detection, its origin and promise for anyone at high risk for cancer, the science behind the screening tests, and insight into how this technology has the potential to shift the cancer paradigm. Guests will include healthcare pioneers and providers, advocates, policymakers, and others who will share their perspectives and experiences with multi-cancer early detection testing. Subscribe to The Cancer SIGNAL to hear more.